Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04461171 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Enhanced Recovery After Surgery in Extremity Sarcoma

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 11 months later Dec 2025 → Dec 2026
See other at-risk trials from Joshua Lawrenz

Record History

  1. Primary completion pushed from Dec 2025 to Dec 2026 Trial status changed: Unknown → Recruiting · Completion pushed from Jun 2026 to Dec 2026v10 Show 2 more changesShow less
    • Trial status changed: Unknown → Recruiting
    • Completion pushed from Jun 2026 to Dec 2026
  2. Changed Registry marked status Unknown; last known: Recruiting
  3. Primary completion date: Dec 2024 to Dec 2025 Completion date: Jun 2025 to Jun 2026v9 Show 1 more changeShow less
    • Completion date: Jun 2025 to Jun 2026
  4. Primary completion date: Dec 2023 to Dec 2024 Completion date: Jun 2024 to Jun 2025v8 Show 1 more changeShow less
    • Completion date: Jun 2024 to Jun 2025
  5. Primary completion date: Dec 2022 to Dec 2023 Completion date: Jun 2023 to Jun 2024 · Eligibility criteria expanded, about 1 wordv7 Show 2 more changesShow less
    • Completion date: Jun 2023 to Jun 2024
    • Eligibility criteria expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

Show 5 earlier versionsHide 5 earlier versions
  1. Primary completion date: Jan 2022 to Dec 2022 Completion date: Dec 2022 to Jun 2023 · Eligibility criteria shortened, about 26 wordsv6 Show 2 more changesShow less
    • Completion date: Dec 2022 to Jun 2023
    • Eligibility criteria shortened, about 26 words

    See this version in full on ClinicalTrials.gov ↗

  2. Trial status: Not Yet Recruiting to Recruiting Primary completion date: Nov 2021 to Jan 2022 · Completion date: Nov 2022 to Dec 2022 · Start date changed from estimate of Nov 2020 to Dec 14, 2020 · 1 morev5 Show 4 more changesShow less
    • Primary completion date: Nov 2021 to Jan 2022
    • Completion date: Nov 2022 to Dec 2022
    • Start date changed from estimate of Nov 2020 to Dec 14, 2020
    • Site details revised
  3. Enrollment target: 64 to 120 Start date: Sep 2020 to Nov 2020 · Primary completion date: Oct 2021 to Nov 2021 · Completion date: Oct 2022 to Nov 2022 · 1 morev4 Show 4 more changesShow less
    • Start date: Sep 2020 to Nov 2020
    • Primary completion date: Oct 2021 to Nov 2021
    • Completion date: Oct 2022 to Nov 2022
    • Eligibility criteria revised

    See this version in full on ClinicalTrials.gov ↗

  4. Lead sponsor: Ginger Holt to Joshua Lawrenz Enrollment target: 30 to 64 · Site contact updated · Study arms: 1 to 2v3 Show 3 more changesShow less
    • Enrollment target: 30 to 64
    • Site contact updated
    • Study arms: 1 to 2
  5. Lead sponsor: Vanderbilt-Ingram Cancer Center to Ginger Holt Start date: Jul 2020 to Sep 2020v2 Show 1 more changeShow less
    • Start date: Jul 2020 to Sep 2020
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Joshua Lawrenz
1 trial monitored
See 1 trial at risk
Sarcoma
951 trials monitored
See 56 trials at risk
The purpose of this study is to demonstrate the efficacy of implementing the enhanced recovery after surgery (ERAS) pathway in a prospective manner to patients undergoing surgical treatment for extremity sarcoma.
Trial Details
NCT Number NCT04461171
Lead Sponsor Joshua Lawrenz
Conditions Sarcoma
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov